<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526786</url>
  </required_header>
  <id_info>
    <org_study_id>16-00016-00</org_study_id>
    <nct_id>NCT00526786</nct_id>
  </id_info>
  <brief_title>Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus</brief_title>
  <acronym>ICE</acronym>
  <official_title>A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSA Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSA Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the CryoSpray
      Ablation System to treat esophageal low grade dysplasia (LGD) or high grade dysplasia (HGD)
      within Barrett's Esophagus (BE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of an estimated 200 subjects with HGD or LGD within BE who are deemed
      inoperable or refuse standard surgical treatment. A maximum of 20 investigational sites will
      participate with a maximum of ten subjects per site.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Reasons
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The eradication of LGD and HGD within BE at 24 months after the final treatment. The primary safety endpoint is the incidence of all adverse events.</measure>
    <time_frame>2 years post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.Eradication of all BE by 24 months after the final treatment. 2.The proportion of lesions that decreased in length by the 24-month follow-up. 3.The proportion of lesions where severity was downgraded by the 24-month follow-up.</measure>
    <time_frame>2 years post treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">78</enrollment>
  <condition>Barrett's Esophagus</condition>
  <condition>High Grade Dysplasia</condition>
  <condition>Low Grade Dysplasia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CryoSpray Ablation System (510(k) NO: K070893)</intervention_name>
    <description>no drug interventions specified</description>
    <other_name>510(k) NO: K070893</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky performance status of 50-100%

          -  Life expectancy greater than 5 years

          -  Hematopoietic, Hepatic and Renal lab clearance

          -  Previous endoscopy with histological confirmation of LGD or HGD within BE

          -  For Group 2, deemed inoperable based on the following criteria: co-morbid conditions
             such as severe heart, lung, kidney or liver disease; or refusal of surgical
             intervention after a thorough unbiased discussion of surgery.

          -  For Group 2, endoscopic ultrasound (EUS) evaluation demonstrating no evidence of
             invasion or metastatic lymph node involvement (T0N0M0 by EUS).

        Exclusion Criteria:

          -  Pregnant, not practicing adequate contraception, intending to become pregnant, or
             lactating at any time during the study (approximately 2 years).

          -  Esophageal stricture preventing passage of endoscope or catheter.

          -  Active esophagitis

          -  EMR performed less than 8 weeks prior to CSA treatment.

          -  EMR performed on greater than 90% circumference of any area of the esophagus.

          -  Any previous esophageal surgery, except fundoplication without complications.

          -  Known history of unresolved drug or alcohol dependency that would limit ability to
             comprehend or follow instructions related to informed consent, post-treatment
             instructions, or follow-up guidelines.

          -  Concurrent enrollment in an investigational drug or device trial that clinically
             interferes with the LCS Dysplasia endpoints.

          -  Psychiatric or other illness deemed by the investigator as an inability to comply with
             this protocol.

          -  Medically unfit or other contraindication to tolerate upper endoscopy.

          -  Inability to tolerate therapy with a proton pump inhibitor (PPI).

          -  Refusal or inability to give consent.

          -  Other active malignancy (except nonmelanoma skin cancer or another cancer for which
             patient is deemed disease-free).

          -  Concurrent chemotherapy.

          -  Prior radiation therapy which involved the esophagus.

          -  Prior adenocarcinoma involving the esophagus or stomach.

          -  Prior or concurrent ablation therapy including, but not limited to, photodynamic
             therapy, multipolar electro coagulation, argon plasma coagulation, laser treatment,
             radio frequency, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Greenwald, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California -Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoboken Universtiy Medical Center</name>
      <address>
        <city>Hoboken</city>
        <state>New Jersey</state>
        <zip>07030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtiy of North Carloina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Reginal Medical Center</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.csamedical.com</url>
    <description>Click here for more information about CryoSpray Ablation</description>
  </link>
  <reference>
    <citation>Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology. 1994 Sep;107(3):747-54.</citation>
    <PMID>8076761</PMID>
  </reference>
  <reference>
    <citation>Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol. 1997 Jan;92(1):27-31.</citation>
    <PMID>8995932</PMID>
  </reference>
  <reference>
    <citation>Ell C, May A, Gossner L, Pech O, Günter E, Mayer G, Henrich R, Vieth M, Müller H, Seitz G, Stolte M. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2000 Apr;118(4):670-7.</citation>
    <PMID>10734018</PMID>
  </reference>
  <reference>
    <citation>Johnston CM, Schoenfeld LP, Mysore JV, Dubois A. Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus. Gastrointest Endosc. 1999 Jul;50(1):86-92.</citation>
    <PMID>10385730</PMID>
  </reference>
  <reference>
    <citation>Johnston MH. Cryotherapy and other newer techniques. Gastrointest Endosc Clin N Am. 2003 Jul;13(3):491-504. Review.</citation>
    <PMID>14629105</PMID>
  </reference>
  <reference>
    <citation>Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005 Dec;62(6):842-8.</citation>
    <PMID>16301023</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Grade Dysplasia</keyword>
  <keyword>High Grade Dysplasia</keyword>
  <keyword>Barrett's Esophagus</keyword>
  <keyword>Cryospray ablation</keyword>
  <keyword>ICE</keyword>
  <keyword>Cryotherapy</keyword>
  <keyword>Cryo</keyword>
  <keyword>CryoSpray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 7, 2014</submitted>
    <returned>August 5, 2014</returned>
    <submitted>June 4, 2015</submitted>
    <returned>July 2, 2015</returned>
    <submitted>July 2, 2015</submitted>
    <returned>July 27, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

